Concepta PLC Result of AGM (9010R)
03 July 2020 - 12:24AM
UK Regulatory
TIDMCPT
RNS Number : 9010R
Concepta PLC
02 July 2020
Concepta PLC
("Concepta" or the "Company")
Result of AGM
Concepta PLC (AIM: CPT), the innovative UK personalised
healthcare company and developer of myLotus(R), the UK's most
accurate home-use fertility tracking and pregnancy self-testing
system, announces that at the Annual General Meeting ("AGM") held
earlier today, all resolutions were duly passed.
Details of voting are provided below:
Resolution For Against
Resolution
1 107,315,949 86,504
------------ ----------
Resolution
2 107,320,669 63,504
------------ ----------
Resolution
3 106,115,669 1,266,784
------------ ----------
Resolution
4 106,120,669 1,286,504
------------ ----------
Resolution
5 106,070,949 1,336,504
------------ ----------
Resolution
6 106,070,949 1,336,504
------------ ----------
Resolution
7 106,120,949 1,286,504
------------ ----------
Resolution
8 105,846,568 1,470,127
------------ ----------
Resolution
9 104,660,762 2,655,653
------------ ----------
Concepta plc www.conceptaplc.com
P enny McCormick , Chief Executive via Walbrook PR
Officer
Maddy Kennedy, Chief Financial
Officer
SPARK Advisory Partners Limited Tel: +44 (0)20 3368 3550
(NOMAD)
Neil Baldwin
Novum Securities (Broker) Tel: +44 (0)20 7399 9400
Colin Rowbury
Walbrook PR Ltd (Media & Investor Tel: +44 (0)20 7933 8780 or concepta@walbrookpr.com
Relations)
Paul McManus Mob: +44(0)7980 541 893
About Concepta PLC ( www.conceptaplc.com )
Concepta PLC is an AIM-quoted pioneering UK healthcare company
that has developed a proprietary product, myLotus(R), targeted at
the personalized mobile health market with a primary focus on
hormone testing and increasing a woman's chances of naturally
getting pregnant and to provide insight to unexplained
infertility.
myLotus(R) is currently the only consumer product which allows
both quantitative and qualitative home (self-test) test measurement
of a woman's personal luteinizing hormone (LH) during ovulation and
human chorionic gonadotropin (hCG) hormone level during pregnancy,
facilitating higher conception rates and early diagnosis of
fertility issues. The proposition of myLotus(R) is to empower women
to better understand their hormone levels and menstrual cycle and
help women conceive naturally by identifying their window of
fertility and optimal time for conception.
The Company has received CE-mark certification for myLotus(R)
and has launched its first product in the UK. The Company is
preparing plans to roll-out across the core EU countries in
2020.
myLotus(R) is expected to be beneficial to users who have been
unable to conceive after 6 months of trying. This highly motivated
target group of women won't typically be offered medical
intervention until after 12 months of unsuccessfully trying to
conceive, with IVF not usually offered until after two years of
trying to conceive. Research indicates couples start to take
positive action ahead of this time typically with little medical
support to help them do so.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGZLLFBBDLLBBF
(END) Dow Jones Newswires
July 02, 2020 10:24 ET (14:24 GMT)
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Apr 2024 to May 2024
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From May 2023 to May 2024